BIONIME (4737) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 華廣

BIONIME (4737) reported revenue of NT$154.1 million for Oct 2026, +12.2% year on year and -14.4% from the previous month. Revenue for Jan–Oct 2026 was NT$1.46 billion (-5.6% year on year).

In Oct 2026, it ranked No. 53 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$178 million24/10Nov 2024 NT$181.6 millionDec 2024 NT$142.6 millionJan 2025 NT$165.9 millionFeb 2025 NT$155.6 million25/02Mar 2025 NT$159.9 millionApr 2025 NT$154.3 millionMay 2025 NT$163.7 millionJun 2025 NT$153.6 million25/06Jul 2025 NT$142.3 millionAug 2025 NT$167.2 millionSep 2025 NT$148.9 millionOct 2025 NT$137.3 million25/10Nov 2025 NT$128.7 millionDec 2025 NT$160.9 millionJan 2026 NT$127.2 millionFeb 2026 NT$110.6 million26/02Mar 2026 NT$167.5 millionApr 2026 NT$141.3 millionMay 2026 NT$141.7 millionJun 2026 NT$143.6 million26/06Jul 2026 NT$145.7 millionAug 2026 NT$150 millionSep 2026 NT$180 millionOct 2026 NT$154.1 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$154.1 million+12.2%-14.4%
Sep 2026NT$180 million+20.9%+20.0%
Aug 2026NT$150 million-10.3%+2.9%
Jul 2026NT$145.7 million+2.4%+1.5%
Jun 2026NT$143.6 million-6.5%+1.3%
May 2026NT$141.7 million-13.5%+0.3%
Apr 2026NT$141.3 million-8.4%-15.6%
Mar 2026NT$167.5 million+4.7%+51.5%
Feb 2026NT$110.6 million-28.9%-13.1%
Jan 2026NT$127.2 million-23.3%-20.9%
Dec 2025NT$160.9 million+12.8%+25.0%
Nov 2025NT$128.7 million-29.1%-6.3%
Oct 2025NT$137.3 million-22.8%-7.8%
Sep 2025NT$148.9 million-8.1%-10.9%
Aug 2025NT$167.2 million+0.2%+17.5%
Jul 2025NT$142.3 million-10.6%-7.4%
Jun 2025NT$153.6 million-9.8%-6.2%
May 2025NT$163.7 million-2.1%+6.1%
Apr 2025NT$154.3 million+12.4%-3.5%
Mar 2025NT$159.9 million-9.7%+2.8%
Feb 2025NT$155.6 million+10.9%-6.2%
Jan 2025NT$165.9 million+9.8%+16.3%
Dec 2024NT$142.6 million-21.0%-21.5%
Nov 2024NT$181.6 million+37.0%+2.0%
Oct 2024NT$178 million+0.9%+9.8%

Jan–Oct 2026 cumulative: NT$1.46 billion (-5.6% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: BIONIME vs PEC / BIONIME vs Lotus Pharm / BIONIME vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16